Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abbott
UroVysion DNA Test superior to standard cytology in diagnosing bladder cancer, study shows
August 18th, 2006
A study in the Journal of Urology has shown UroVysion, a DNA-based urine test that detects genetic changes in bladder cells, has almost twice the sensitivity of conventional urine cytology tests for the initial diagnosis of bladder cancer in patients with hematuria suspected of having bladder cancer. Sensitivity refers to the likelihood that a patient with bladder cancer will have a positive test result and is a standard indicator of the predictive value of a diagnostic test. Because bladder cancer only accounts for about 10 percent of patients with hematuria, a delay between symptoms and diagnosis is common and has been shown to adversely...
Source: Biotech Law Weekly (2006-08-18)
|
